PMID- 26784019 OWN - NLM STAT- MEDLINE DCOM- 20170110 LR - 20170111 IS - 1423-0356 (Electronic) IS - 0025-7931 (Linking) VI - 91 IP - 2 DP - 2016 TI - The Impact of Obstructive Sleep Apnea and Tobacco Smoking on Endothelial Function. PG - 124-31 LID - 10.1159/000443527 [doi] AB - BACKGROUND: Endothelial dysfunction has been recognized to occur in the context of obstructive sleep apnea (OSA) or tobacco smoking. However, the deleterious effect on vascular function with concurrence of both conditions is largely unknown. OBJECTIVE: To investigate whether the concurrence of OSA and smoking poses an additive detriment to endothelial dysfunction. METHODS: Chinese men without a history of chronic medical illness were invited to complete a questionnaire including smoking pack-year exposure, polysomnography and peripheral arterial tonometry (PAT) for endothelial function. Serum 8-isoprostane, advanced oxidation protein products (AOPP) and monocyte chemo-attractant protein-1 (MCP-1) were measured. RESULTS: 114 men were successfully enrolled. PAT ratio, adjusted for age and body mass index, correlated inversely with overall severity of OSA: apnea-hypopnea index (AHI), r = -0.160 (p = 0.092); oxygen desaturation index, r = -0.214 (p = 0.024); duration of oxygen saturation <90%, r = -0.219 (p = 0.020); and minimum oxygen saturation, r = 0.250 (p = 0.008). The PAT ratio decreased with increasing pack-year group (p = 0.018). It was lower with concurrent smoking history and moderate-severe OSA (AHI >/=15/h) compared to having one or neither factor (p = 0.011). Serum levels of 8-isoprostane and AOPP were positively related to severity of OSA, while MCP-1 correlated with smoking quantity. Multiple linear regression analyses showed that severity of intermittent hypoxia, MCP-1 and pack-year exposure were independent predictors of PAT ratio. CONCLUSION: While OSA, in particular intermittent hypoxemia, and tobacco smoking were independent risk factors, the concurrence of moderate-severe OSA and smoking was associated with the most severe impairment in endothelial function. CI - (c) 2016 S. Karger AG, Basel. FAU - Lui, Macy Mei Sze AU - Lui MM AD - Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, SAR, China. FAU - Mak, Judith Choi Wo AU - Mak JC FAU - Lai, Agnes Yuen Kwan AU - Lai AY FAU - Hui, Christopher Kim Ming AU - Hui CK FAU - Lam, Jamie Chung Mei AU - Lam JC FAU - Lam, David Chi Leung AU - Lam DC FAU - Ip, Mary Sau Man AU - Ip MS LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20160120 PL - Switzerland TA - Respiration JT - Respiration; international review of thoracic diseases JID - 0137356 RN - 0 (Advanced Oxidation Protein Products) RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) RN - 27415-26-5 (8-epi-prostaglandin F2alpha) RN - B7IN85G1HY (Dinoprost) SB - IM MH - Adult MH - Advanced Oxidation Protein Products/blood MH - Chemokine CCL2/blood MH - Cohort Studies MH - Dinoprost/analogs & derivatives/blood MH - Endothelium, Vascular/*physiopathology MH - Humans MH - Male MH - Middle Aged MH - Sleep Apnea, Obstructive/blood/*physiopathology MH - Smoking/blood/*physiopathology EDAT- 2016/01/20 06:00 MHDA- 2017/01/11 06:00 CRDT- 2016/01/20 06:00 PHST- 2015/05/04 00:00 [received] PHST- 2015/12/18 00:00 [accepted] PHST- 2016/01/20 06:00 [entrez] PHST- 2016/01/20 06:00 [pubmed] PHST- 2017/01/11 06:00 [medline] AID - 000443527 [pii] AID - 10.1159/000443527 [doi] PST - ppublish SO - Respiration. 2016;91(2):124-31. doi: 10.1159/000443527. Epub 2016 Jan 20.